- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02704962
Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine
March 4, 2016 updated by: Ching-Hua Lin, MD, PhD, Kaohsiung Kai-Suan Psychiatric Hospital
A Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia
The investigators hypothesis is that an antipsychotic drug combination of low-dose olanzapine plus low-dose trifluoperazine is similar to regular-dose olanzapine monotherapy in efficacy and safety for treatment of schizophrenia.The goal of this study is to compare the efficacy and safety of the olanzapine (10 mg/d) and olanzapine (5 mg/d) plus trifluoperazine (5 mg/d) in the treatment of acute psychotic exacerbations of schizophrenia.
Study Overview
Detailed Description
Antipsychotic monotherapy is recognized as the treatment of choice for patients with schizophrenia.
Surveys have shown that antipsychotic polypharmacy are frequently prescribed, yet few randomized, double-blind clinical trials have examined this practice.
Olanzapine, an atypical antipsychotic agent, has low incidence of extrapyramidal symptom but with high cost compared to trifluoperazine.
It has been reported that mean doses of typical antipsychotics less than 600 mg per day of chlorpromazine or its equivalent has no higher risk of extrapyramidal symptom than atypical antipsychotics.
The objective of the study is to compare the efficacy and safety of the olanzapine (10 mg per day) and olanzapine (5 mg per day) plus trifluoperazine (5 mg per day) in the treatment of acute psychotic exacerbations of schizophrenia.
In this 6-week, double-blind, fixed-dose study, patients with schizophrenia are randomly assigned to olanzapine (10 mg per day)) or olanzapine (5 mg per day) plus trifluoperazine (5 mg per day).
The hypothesis is that the two treatment groups have the similar efficacy and safety, but different cost.
The primary efficacy measure is change from baseline in Positive and Negative Syndrome Scale (PANSS) total scores; secondary outcomes include Clinical Global Impression-Severity (CGI-S), the Calgary Depression Scale for Schizophrenia (CDSS), Global Assessment of Functioning Scale (GAF), Short Form-36 (SF-36), Mini Mental State Examination (MMSE).
Safety assessments include the change from baseline on Simpson-Angus Rating Scale (SAS), Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Scale (BAS), and UKU Side-effects Rating Scale, and the change from baseline in prolactin levels, body weight, vital sign, blood pressure, Bazett's correction of QT interval (QTc interval), fasting glucose level, and lipid panel (cholesterol, high density lipid protein, low density lipid protein, and triglyceride).
Study Type
Interventional
Enrollment (Actual)
94
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kaohsiung, Taiwan, 802
- Kai-Suan Psychiatric Hospital
-
Kaohsiung, Taiwan
- Kai-Suan Psychiatric Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- were physically healthy and had all laboratory parameters within normal limits
- were aged 18 to 55 years
- satisfied the DSM-IV criteria for schizophrenia
- had baseline Clinical Global Impression-Severity of Illness (CGI-S) scale score of 4 or greater
- had no DSM-IV diagnosis of substance abuse or dependence (including alcohol)
- had not received depot antipsychotic drugs for the preceding 3 months
- gave written informed consent to participate in the study after a full explanation of the study's aims and procedures.
Exclusion Criteria:
- those with a history of serious adverse reaction to olanzapine or trifluoperazine or a history of tardive dyskinesia or neuroleptic malignant syndrome
- female subjects who were pregnant or at risk for pregnancy or lactation
- those that had a diagnosis of treatment-resistant schizophrenia or having previously received clozapine or electroconvulsive therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: trifluoperazine plus olanzapine
trifluoperazine 5mg/day + olanzapine 5mg/day
|
trifluoperazine 5mg/d
Other Names:
|
Active Comparator: full-dose olanzapine
olanzapine 10mg/day
|
trifluoperazine 5mg/d
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The changes in the Positive and Negative Syndrome Scale (PANSS) scores from baseline to the end of the study.
Time Frame: The PANSS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The PANSS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The changes in the Clinical Global Impression-Severity (CGI-S) scores from baseline to the end of the study.
Time Frame: The CGI-S was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The CGI-S was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The changes in the Calgary Depression Scale for Schizophrenia (CDSS) scores from baseline to the end of the study.
Time Frame: The CDSS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The CDSS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The changes in the Global Assessment of Functioning (GAF) scores from baseline to the end of the study.
Time Frame: The GAF was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The GAF was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The changes in the Short-Form 36 (SF-36) scores from baseline to week 6.
Time Frame: The SF-36 was rated at baseline and again at week 6.
|
The SF-36 was rated at baseline and again at week 6.
|
The changes in the Mini Mental State Examination (MMSE) scores from baseline to week 6.
Time Frame: The MMSE was rated at baseline and again at week 6.
|
The MMSE was rated at baseline and again at week 6.
|
The changes in the Simpson-Angus Rating Scale (SAS) scores from baseline to the end of the study.
Time Frame: The SAS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The SAS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The changes in the Abnormal Involuntary Movement Scale (AIMS) scores from baseline to the end of the study.
Time Frame: The AIMS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The AIMS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The changes in the Barnes Akathisia Scale (BAS) scores from baseline to the end of the study.
Time Frame: The BAS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The BAS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The changes in the UKU Side-effects Rating Scale (UKU) scores from baseline to the end of the study.
Time Frame: The UKU was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The UKU was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The changes in the Bazett's correction of QT interval (QTc interval) from baseline to week 6.
Time Frame: The QTc interval was assayed at baseline and again at week 6.
|
The QTc interval was assayed at baseline and again at week 6.
|
The changes in the body weight from baseline to the end of the study.
Time Frame: The body weight was assayed at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The body weight was assayed at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination).
|
The changes in the fasting glucose level from baseline to week 6.
Time Frame: The fasting glucose level was assayed at baseline and again at week 6.
|
The fasting glucose level was assayed at baseline and again at week 6.
|
The changes in the prolactin level from baseline to week 6.
Time Frame: The prolactin level was assayed at baseline and again at week 6.
|
The prolactin level was assayed at baseline and again at week 6.
|
The changes in the cholesterol level from baseline to week 6.
Time Frame: The cholesterol level was assayed at baseline and again at week 6.
|
The cholesterol level was assayed at baseline and again at week 6.
|
The changes in the high density lipoprotein (HDL) level from baseline to week 6.
Time Frame: The HDL level was assayed at baseline and again at week 6.
|
The HDL level was assayed at baseline and again at week 6.
|
The changes in the low density lipoprotein (LDL) level from baseline to week 6.
Time Frame: The LDL level was assayed at baseline and again at week 6.
|
The LDL level was assayed at baseline and again at week 6.
|
The changes in the triglyceride level from baseline to week 6.
Time Frame: The triglyceride level was assayed at baseline and again at week 6.
|
The triglyceride level was assayed at baseline and again at week 6.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ching-Hua Lin, MD, PhD, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City, Taiwan
- Study Chair: Cheng-Chung Cheng, MD, PhD, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City, Taiwan
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lin CH, Wang FC, Lin SC, Huang YH, Chen CC, Lane HY. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. Int Clin Psychopharmacol. 2013 Sep;28(5):267-74. doi: 10.1097/YIC.0b013e3283633a83.
- Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31-41. doi: 10.1016/S0140-6736(08)61764-X. Epub 2008 Dec 6.
- Lin CH, Kuo CC, Chou LS, Chen YH, Chen CC, Huang KH, Lane HY. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol. 2010 Oct;30(5):518-25. doi: 10.1097/JCP.0b013e3181f28dff.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
February 1, 2016
Study Registration Dates
First Submitted
February 27, 2016
First Submitted That Met QC Criteria
March 4, 2016
First Posted (Estimate)
March 10, 2016
Study Record Updates
Last Update Posted (Estimate)
March 10, 2016
Last Update Submitted That Met QC Criteria
March 4, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Olanzapine
Other Study ID Numbers
- KSPH-2011-22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on full-dose olanzapine
-
University of TorontoCompleted
-
Colorado State UniversityNaturex-DbsCompletedAging | Endothelial DysfunctionUnited States
-
University of Sao Paulo General HospitalCompleted
-
University of OxfordEuropean CommissionCompletedMalaria | Plasmodium FalciparumUnited Kingdom
-
University of North Carolina, Chapel HillNaturex SACompleted
-
EpicentreKenya Medical Research Institute; LSHTM; Universite Abdou Moumouni de Niamey UAMActive, not recruitingPneumococcal CarriageNiger
-
University Hospital, AntwerpNot yet recruitingHypersensitivity | Anaphylaxis | Allergic Reaction | Perioperative Complication | Immediate Hypersensitivity | Hypersensitivity, Drug | Anaphylactic ReactionBelgium
-
The University of Texas Health Science Center,...Samsung ElectronicsCompletedChest X-ray for Clinical EvaluationUnited States
-
Valneva Austria GmbHRecruitingChikungunya Virus InfectionDominican Republic, Honduras
-
GlaxoSmithKlineActive, not recruitingInfections, Soft TissueUnited States, South Africa, Australia, India, New Zealand, United Kingdom, Poland